This is the first report to describe dose dependency in the effects of tolvaptan treatment for autosomal dominant polycystic kidney disease.The weight-adjusted average daily dose of tolvaptan was found to be a factor that significantly affected the change in eGFR.If a patient shows tolerance, increasing the tolvaptan dose to the maximum should be considered.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786106 | PMC |
| http://dx.doi.org/10.34067/KID.0007342020 | DOI Listing |
Publication Analysis
Top Keywords
autosomal dominant
8
dominant polycystic
8
polycystic kidney
8
dose-dependent tolvaptan
4
tolvaptan renal
4
renal prognosis
4
prognosis patients
4
patients autosomal
4
kidney disease
4
disease report
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!